Replies to post #823238 on NorthWest Biotherapeutics Inc (NWBO)

[manibiotech]

Only rational conditions for GBM/rGBM I can think of are:
- Mthylated vs non methylated
- All GBM/rGBM and Phase 4 after approval

Not sure how else can there be a conditional approval for GBM/rGBM ??

[beartrap12]

anthihama, remember that someone posted on this board a few weeks/months ago that conditional approval is a common tactic MHRA uses in approving a new medicine/treatment, and requires the company to collect data on use and response to treatment for a period of time. Also remember that the UK is big on companies proving that their treatment works, unlike the US. Approval ends if data fails to proof efficacy. I like this approach. It gets rid of useless drugs.
Collecting data is something NWBO has done with DCVax-L through the compassionate program since it's inception, I believe, so it can be used in securing the first DCVax-L for DCVax. I don't see it being an issue for us.

I hope that poster will repost his comments and points to his source.

[Goats'nCrows]

We have an imperfect trial with imperfect data hence the initial blowback to the JAMA publication. IMO it's nothing that even raises an eyebrow.

GLTA